29 Jun 2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
11 Jun 2020 Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
17 Jul 2019 We are proud to have been recognised by StartUp City Magazine as one of the most promising European Biotech startups in 2019!
